UK study counts how many preterm babies get eylea for eye disease

NCT ID NCT06315556

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This observational study collects data from UK preterm babies with retinopathy of prematurity (ROP) who are treated with the drug aflibercept (Eylea) using a paediatric dosing device. The main goal is to count how many babies receive this treatment and decide if there are enough to run a future long-term safety study. No extra visits or tests are needed—only existing hospital records are used.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aflibercept (Eylea)
What this could lead to: If enough babies are treated, this study could pave the way for a larger safety study on long-term effects of Eylea in preterm infants with ROP.
What could go wrong: This is an observational study that only counts cases and describes patient traits—it does not test whether the treatment works or is safe. The number of treated babies may be too small to proceed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRETERM INFANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinopathy of prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRETERM INFANTS RETINOPATHY OF PREMATURITY

Contacts and locations

Locations

Many locations
RECRUITING

Multiple Locations, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.